TTrialPathMatch Me to Trials
← Back to trials
RecruitingAtrial Fibrillation

A Study of VARIPULSE Catheter in Participants With Persistent Atrial Fibrillation Undergoing Pulmonary Vein and Superior Vena Cava Isolation

Eligible age

18–80 yrs

Accepts

All genders

Locations

13 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to assess how safe VARIPULSE catheter system is for treatment of a heart rhythm disease called persistent atrial fibrillation (PsAF) in participants who are having a catheter ablation procedure (treat heart rhythm disease). This includes isolation of pulmonary vein and superior vena cava (heart veins; pulmonary vein isolation \[PVI\] and superior vena cava isolation \[SVCI\]), with or without another technique called posterior wall isolation (PWI). Also, to assess how safe it is for participants who are having a catheter ablation procedure and at the same time receiving another procedure called left atrial appendage occlusion (LAAO; to reduce stroke risk). Additionally, to assess how well VARIPULSE catheter system works over a long period of time for treatment of PsAF in participants undergoing catheter ablation for PVI, SVCI and SVCI+PWI.

Sponsor: Biosense Webster, Inc.

You may qualify if…

  • ✓ Participant has been diagnosed with symptomatic persistent atrial fibrillation (PsAF), which is defined as continuous atrial fibrillation (AF) sustained beyond 7 days in duration and less than 365 days in duration, documented by: i. A physician's note documenting diagnosis of symptomatic PsAF, as defined above; and ii. Two electrocardiograms (ECGs) showing continuous AF, with electrocardiogram taken at least 7 days apart (electrocardiograms cannot be greater than (\>) 365 days prior to enrollment); or iii. A 24-hour arrhythmia monitor documenting continuous AF within the last 365 days
  • ✓ Participant is aged 18 - 80 years at the time of informed consent
  • ✓ Participant is willing and capable of providing informed consent
  • ✓ Participant is able and willing to comply with all pre-, post- and follow-up testing and requirement
  • ✓ Left atrial appendage occlusion (LAAO) concomitant subset:
  • ✓ \- Participant is clinically indicated for a LAAO procedure

You may not qualify if…

  • ✕ Participant has continuous AF \> 365 days (longstanding persistent AF)
  • ✕ Participant has AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause (for example, untreated documented obstructive sleep apnea, acute alcohol toxicity, etc.)
  • ✕ Participant has had previous surgical or catheter ablation for AF
  • ✕ Participant is known to require ablation outside the left atrium (LA), superior vena cava (SVC), and the cavotricuspid isthmus (CTI) region (for example, atrioventricular reentrant tachycardia, atrioventricular nodal reentry tachycardia, ventricular tachycardia and Wolff-Parkinson-White)
  • ✕ Participant has LA (left atrial) anteroposterior \>= 55 millimeter (mm) (by magnetic resonance imaging \[MRI\], computed tomography \[CT\], or transthoracic echocardiogram \[TTE\]), or if LA diameter is not available, non-index volume \>100 milliliter (mL) confirmed within 365 days prior to enrollment
  • ✕ Participant has LA thrombus confirmed by imaging within 48 hours prior to the procedure
  • ✕ Participant has severely compromised left ventricular ejection fraction (left ventricle ejection fraction \[LVEF\] less than \[\<\] 40 percent \[%\]) confirmed by imaging performed within 180 days prior to enrollment
  • ✕ Participant has uncontrolled heart failure or New York heart association (NYHA) Class III or IV functional classification

Where it's recruiting

Alabama

Birmingham

Arizona

Tucson

Arkansas

Jonesboro

California

Santa Monica

Colorado

Aurora

Connecticut

Hartford

Florida

Atlantis

Kentucky

Edgewood

Michigan

Traverse City

New York

The Bronx

Oklahoma

Oklahoma City

Pennsylvania

Philadelphia

Source: ClinicalTrials.gov · NCT07527299 · last updated 2026-11-03

A Study of VARIPULSE Catheter in Participants With Persistent Atrial F · TrialPath